Drug Profile
Research programme: therapeutic antibodies - LEO Pharma/Morphosys
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator LEO Pharma; MorphoSys
- Class Antibodies; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for research development in Skin-disorders in Denmark (Parenteral)
- 28 Dec 2020 No recent reports of development identified for research development in Skin-disorders in Germany (Parenteral)
- 02 Nov 2016 Early research in Skin disorders in Denmark (Parenteral)